drugset / Trial / NCT02454608

Trial of Verapamil in Chronic Rhinosinusitis

NCT02454608

Terminated 29 enrolled Benjamin Bleier
RandomizedParallel-groupTriple-blindTreatment

Summary

Verapamil is an L-type calcium channel blocker(CCB) which has been shown to reduce inflammation in a variety of tissues. Verapamil has also been shown to improve eosinophilic inflammation in an animal model of asthma and also functions as a P-glycoprotein(P-gp) inhibitor. A major subtype of chronic rhinosinusitis(CRS) is characterized by eosinophilic inflammation as well as P-gp overexpression. The goal of this study is to therefore see whether Verapamil may be used to treat CRS.

Timeline

Start
2015-05
Primary completion
2016-03
Completion
2017-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Verapamil Other / unclassified 80 mg Oral